Acute Hepatic Porphyrias: Review and Recent Progress

Bruce Wang, Sean Rudnick, Brent Cengia, Herbert L. Bonkovsky – 20 December 2018 – The acute hepatic porphyrias (AHPs) are a group of four inherited diseases of heme biosynthesis that present with episodic, acute neurovisceral symptoms. The four types are 5‐aminolevulinic acid (ALA) dehydratase deficiency porphyria, acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria. Their diagnoses are often missed or delayed because the clinical symptoms mimic other more common disorders.

Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co‐infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End‐Stage Liver Disease as Compared to HCV Mono‐infected Patients

Dominique Salmon‐Ceron, Pierre Nahon, Richard Layese, Valérie Bourcier, Philippe Sogni, Firouze Bani‐Sadr, Etienne Audureau, Laurence Merchadou, François Dabis, Linda Wittkop, Françoise Roudot‐Thoraval, for the ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups – 19 December 2018 – It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease.

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System

Elizabeth C. Goode, Allan B. Clark, George F. Mells, Brijesh Srivastava, Kelly Spiess, William T.H. Gelson, Palak J. Trivedi, Kate D. Lynch, Edit Castren, Mette N. Vesterhus, Tom H. Karlsen, Sun‐Gou Ji, Carl A. Anderson, Douglas Thorburn, Mark Hudson, Michael A. Heneghan, Mark A. Aldersley, Andrew Bathgate, Richard N. Sandford, Graeme J. Alexander, Roger W. Chapman, Martine Walmsley, UK‐PSC Consortium, Gideon M. Hirschfield, Simon M.

Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma

Derek Lee, Iris Ming‐Jing Xu, David Kung‐Chun Chiu, Josef Leibold, Aki Pui‐Wah Tse, Macus Hao‐Ran Bao, Vincent Wai‐Hin Yuen, Cerise Yuen‐Ki Chan, Robin Kit‐Ho Lai, Don Wai‐Ching Chin, Daniel For‐Fan Chan, Tan‐To Cheung, Siu‐Ho Chok, Chun‐Ming Wong, Scott W. Lowe, Irene Oi‐Lin Ng, Carmen Chak‐Lui Wong – 18 December 2018 – Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers worldwide which lacks effective treatment. Cancer cells experience high levels of oxidative stress due to increased generation of reactive oxygen species (ROS).

Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer

Roslin Y. Docta, Tiago Ferronha, Joseph P. Sanderson, Thomas Weissensteiner, George R. Pope, Alan D. Bennett, Nicholas J. Pumphrey, Zoltan Ferjentsik, Laura L. Quinn, Guy E. Wiedermann, Victoria E. Anderson, Manoj Saini, Miguel Maroto, Elliot Norry, Andrew B. Gerry – 18 December 2018 – Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic options. Alpha‐fetoprotein (AFP) is often expressed at high levels in HCC and is an established clinical biomarker of the disease.

Gene Silencing With siRNA (RNA Interference): A New Therapeutic Option During Ex Vivo Machine Liver Perfusion Preservation

Max F. Thijssen, Isabel M. A. Brüggenwirth, Andrew Gillooly, Anastasia Khvorova, Timothy F. Kowalik, Paulo N. Martins – 18 December 2018 – RNA interference (RNAi) is a natural process of posttranscriptional gene regulation that has raised a lot of attention culminating with the Nobel Prize in Medicine in 2006. RNAi‐based therapeutics have been tested in experimental transplantation to reduce ischemia/reperfusion injury (IRI) with success.

Subscribe to